Tyrosine News and Research RSS Feed - Tyrosine News and Research

Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. [More]
Breast cancer cells use new signaling pathway to cope with lack of oxygen levels inside tumors

Breast cancer cells use new signaling pathway to cope with lack of oxygen levels inside tumors

Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, and led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University. [More]
Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. [More]
Salvage alloSCT remains option for progressing CML patients

Salvage alloSCT remains option for progressing CML patients

Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure. [More]
Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe. [More]
Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia. [More]
Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

Defects in cerebrospinal fluid flow may contribute to scoliosis during adolescence

A new study in zebrafish suggests that irregular fluid flow through the spinal column brought on by gene mutations is linked to a type of scoliosis that can affect humans during adolescence. [More]
Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Cabozantinib drug can extend lives of patients with advanced renal cell carcinoma

Data presented today at the American Society of Clinical Oncology congress showed that cabozantinib, a next generation tyrosine kinase inhibitor (TKI) can extend the lives of patients by nearly two years following failure of one or more anti-angiogenic therapies almost five months longer than everolimus, a current standard of care therapy. [More]
New study identifies PDGFRα as key molecule for HCMV viral entry

New study identifies PDGFRα as key molecule for HCMV viral entry

A publication in the scientific journal Nature Microbiology identifies PDGFRα as the receptor for the trimeric gHgLgO complex of Human cytomegalovirus (HCMV). [More]
Myricitrin may play role in preventing neuronal degeneration in Parkinson's disease

Myricitrin may play role in preventing neuronal degeneration in Parkinson's disease

A new study has shown that myricitrin, a flavinoid with antioxidant and anti-inflammatory activity that is present inedible plants and fruit, can protect mouse brains from the loss of dopamine-producing neurons caused by neurotoxicity. [More]
Early-life stress may lead to functional dyspepsia in adulthood

Early-life stress may lead to functional dyspepsia in adulthood

Traumatic events early in life can increase levels of norepinephrine—the primary hormone responsible for preparing the body to react to stressful situations—in the gut, increasing the risk of developing chronic indigestion and anxiety during adulthood, a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology reports. [More]
Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

Chemical compound eCF506 may be highly effective at blocking growth of breast cancer cells

A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research. [More]
AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca, MedImmune to provide update on extensive oncology pipeline at ASCO 2016

AstraZeneca and its global biologics research and development arm, MedImmune, will provide an update on their extensive oncology pipeline at the annual meeting of the American Society of Clinical Oncology in Chicago, USA, on 3-7 June 2016. [More]
Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic HSCT offers good survival for select TKI-refractory CML patients

Allogeneic hematopoietic stem cell transplantation is associated with a high rate of survival for carefully chosen chronic myeloid leukaemia patients who do not respond well to tyrosine kinase inhibitor therapy, research suggests. [More]
Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

The first-line treatment and monitoring of patients with chronic phase-chronic myeloid leukaemia is in accordance with the European LeukaemiaNet recommendations, finds a real-world clinical practice study. [More]
EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators. [More]
CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined

Treatment-free remission may be feasible in many patients with chronic myeloid leukaemia, say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase inhibitor therapy. [More]
Novel therapeutic approach to treat leukaemia patients

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms. [More]
Study shows inhibition of SHP-2 enzyme can diminish lupus symptoms

Study shows inhibition of SHP-2 enzyme can diminish lupus symptoms

Researchers at Beth Israel Deaconess Medical Center have identified an enzyme that is significantly elevated in mouse models of systemic lupus erythematosus and in blood samples of patients with lupus. [More]
New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

Obstetricians and midwives are today welcoming the publication of new NICE guidance recommending the use of a new test from Roche Diagnostics that can rule-out the development of the life threatening condition, pre-eclampsia, within one week in pregnant women. [More]
Advertisement
Advertisement